BCR-ABL PCR
A molecular test that measures the BCR-ABL transcript and monitors response in certain leukemias.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Confirm the presence of BCR-ABL transcripts.
- Monitoring molecular responses during therapy.
Informs decisions
- Diagnosis of chronic myeloid leukemia and some acute lymphoblastic leukemia.
- Assessment of the depth of response to targeted therapy.
How the test is done
Genetic material from blood or bone marrow is examined by quantitative methods.
- Sample type
- Blood or bone marrow
- Estimated result time
- Generally one to two weeks.
Limitations
- The result values need to be read according to the international scale used by the laboratory.
- Regular checks are required to ensure response trends are readable.
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Leukemia
Cancer type
Reason: Memerlukan pemeriksaan
- BCR-ABL
Biomarker
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.